Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth Cusi

Showing results (31-40 of 189) with videos related to

Pageof 19
Sort By:
The Lancet. Diabetes & Endocrinology|September 4, 2018
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategiesNorbert Stefan, Hans-Ulrich Häring, Kenneth Cusi
Trends in Endocrinology and Metabolism: TEM|December 18, 2016
Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment StrategiesNishanth E Sunny, Fernando Bril, Kenneth Cusi
Journal of Magnetic Resonance Imaging : JMRI|January 17, 2012
Comparison of visceral adipose tissue quantification on water suppressed and nonwater-suppressed MRI at 3.0 TeslaAnqi Zhou, Horacio Murillo, Kenneth Cusi, et al.
Current Diabetes Reports|April 30, 2013
The future of thiazolidinedione therapy in the management of type 2 diabetes mellitusHanford Yau, Kathya Rivera, Romina Lomonaco, et al.
The Journal of Clinical Endocrinology and Metabolism|March 9, 2019
Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 DiabetesDiana Barb, Fernando Bril, Srilaxmi Kalavalapalli, et al.
The Journal of Clinical Endocrinology and Metabolism|January 12, 2010
Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndromeRenata Belfort, Rachele Berria, John Cornell, et al.
Diabetes Spectrum : a Publication of the American Diabetes Association|February 22, 2024
Making Sense of the Nonalcoholic Fatty Liver Disease Clinical Practice Guidelines: What Clinicians Need to KnowKenneth Cusi, Jeff Budd, Eric Johnson, et al.
Drugs|January 19, 2013
Nonalcoholic fatty liver disease: current issues and novel treatment approachesRomina Lomonaco, Nishanth E Sunny, Fernando Bril, et al.
The Journal of Clinical Endocrinology and Metabolism|March 22, 2026
Patients with MASLD Exhibit In Vivo Changes in Hepatic Response to Oral Fructose ConsumptionFernando Bril, Sean C Forbes, Srilaxmi Kalavalapalli, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|July 5, 2023
Identification of High-Risk Patients With Nonalcoholic Fatty Liver Disease in Endocrinology ClinicsZobair M Younossi, Linda Henry, Scott Isaacs, et al.
Pageof 19

Showing results (31-40 of 189) with videos related to

Sort By:
Pageof 19
The Lancet. Diabetes & Endocrinology|September 4, 2018
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategiesNorbert Stefan, Hans-Ulrich Häring, Kenneth Cusi
Trends in Endocrinology and Metabolism: TEM|December 18, 2016
Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment StrategiesNishanth E Sunny, Fernando Bril, Kenneth Cusi
Journal of Magnetic Resonance Imaging : JMRI|January 17, 2012
Comparison of visceral adipose tissue quantification on water suppressed and nonwater-suppressed MRI at 3.0 TeslaAnqi Zhou, Horacio Murillo, Kenneth Cusi, et al.
Current Diabetes Reports|April 30, 2013
The future of thiazolidinedione therapy in the management of type 2 diabetes mellitusHanford Yau, Kathya Rivera, Romina Lomonaco, et al.
The Journal of Clinical Endocrinology and Metabolism|March 9, 2019
Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 DiabetesDiana Barb, Fernando Bril, Srilaxmi Kalavalapalli, et al.
The Journal of Clinical Endocrinology and Metabolism|January 12, 2010
Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndromeRenata Belfort, Rachele Berria, John Cornell, et al.
Diabetes Spectrum : a Publication of the American Diabetes Association|February 22, 2024
Making Sense of the Nonalcoholic Fatty Liver Disease Clinical Practice Guidelines: What Clinicians Need to KnowKenneth Cusi, Jeff Budd, Eric Johnson, et al.
Drugs|January 19, 2013
Nonalcoholic fatty liver disease: current issues and novel treatment approachesRomina Lomonaco, Nishanth E Sunny, Fernando Bril, et al.
The Journal of Clinical Endocrinology and Metabolism|March 22, 2026
Patients with MASLD Exhibit In Vivo Changes in Hepatic Response to Oral Fructose ConsumptionFernando Bril, Sean C Forbes, Srilaxmi Kalavalapalli, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|July 5, 2023
Identification of High-Risk Patients With Nonalcoholic Fatty Liver Disease in Endocrinology ClinicsZobair M Younossi, Linda Henry, Scott Isaacs, et al.
Pageof 19